Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

2007879 citationsJournal Articlebronze Open Access

Authors

U. Gatzemeier · Asklepios Fachkliniken München-Gauting

A Płużańska · Asklepios Fachkliniken München-Gauting

Aleksandra Szczęsna · Asklepios Fachkliniken München-Gauting

E. Kaukel · Asklepios Fachkliniken München-Gauting

Jaromı́r Roubec · Asklepios Fachkliniken München-Gauting

Flavio De Rosa · Asklepios Fachkliniken München-Gauting

Janusz Milanowski

Abstract

Erlotinib with concurrent cisplatin and gemcitabine showed no survival benefit compared with chemotherapy alone in patients with chemotherapy-naïve advanced NSCLC.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 25, Issue 12, pp. 1545-1552

DOI: 10.1200/jco.2005.05.1474

Field-Weighted Citation Impact: 72.65